QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

PCRX

QT60Pacira BioSciences, Inc.
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·USA
Latest market price
22.33
-0.31-1.37%
OverviewShort InterestFilings
PCRXQT60Pacira BioSciences, Inc.·NASDAQ
OverviewShort InterestFilings
22.33-1.37%
TA
Loading chart...
Screen all →
TAK+1.36%$15.63HLN+1.01%$8.96TEVA-3.32%$31.48VTRS-2.29%$15.37ELAN+3.55%$24.22RDY+1.06%$13.29RGC-18.96%$12.01LNTH+0.65%$103.86
Snapshot
Index-P/E178.29EPS (ttm)
0.12
Insider Own-
Shs Outstand-
Perf Week-4.41%
Market Cap890.54MForward P/E6.18EPS next Y3.61Insider Trans-Shs Float-Perf Month0.09%
Enterprise Value1.16BPEG-EPS next Q0.64Inst Own-Short Float-Perf Quarter-1.06%
Income4.99MP/S1.21EPS this Y2297.49%Inst Trans-Short Ratio-Perf Half Y-14.71%
Sales734.87MP/B1.40EPS next Y25.65%ROA0.43%Short Interest-Perf YTD-13.72%
Book/sh-P/C6.44EPS next 5Y16.23%ROE0.73%52W High27.64 -19.21%Perf Year-8.45%
Cash/sh-P/FCF6.71EPS past 3/5Y-ROIC0.80%52W Low18.80 18.78%Perf 3Y-
Dividend Est.-EV/EBITDA9.78Sales past 3/5Y2.87% 11.04%Gross Margin79.34%Volatility2.53% 2.67%Perf 5Y-
Dividend TTM-EV/Sales1.57EPS Y/Y TTM221.40%Oper. Margin3.09%ATR (14)0.88Perf 10Y-
Dividend Ex-Date-Quick Ratio3.35Sales Y/Y TTM4.85%Profit Margin0.70%RSI (14)40.54Recom2.69
Dividend Gr. 3/5Y-Current Ratio4.73EPS Q/Q-3.23%SMA20-3.22%Beta0.41Target Price32.00
Payout0.00%Debt/Eq0.63Sales Q/Q4.73%SMA50-5.52%Rel Volume1.85Prev Close22.64
Employees788LT Debt/Eq0.64EarningsAug 04SMA200-4.99%Avg Volume514.33KPrice22.33
IPO DateFeb 03, 2011Option/ShortYes / YesEPS/Sales Surpr.-1.64% 2.91%Net Debt/EBITDA2.25Volume950,971Change-1.37%
Analyst Ratings
DateActionAnalystRatingTarget
May-01-26ReiteratedNeedhamBuy$63 → $32
Dec-08-25InitiatedBarclaysEqual Weight$24 → $27
Feb-28-25ReiteratedH.C. WainwrightBuy$39 → $48
Feb-28-25ReiteratedBarclaysOverweight$24
Jan-30-25ReiteratedTruist Financial$8.00 → $25
Jan-30-25UpgradeTruist SecuritiesSell → Hold
Nov-07-24ReiteratedPiper SandlerOverweight$42 → $12
Sep-24-24ReiteratedJefferiesBuy$36 → $18
Aug-13-24ReiteratedTruist Financial$8.00
Aug-13-24DowngradeTruist SecuritiesBuy → Sell
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue735726701
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A151150170
Gross Profit583577531
Selling, General and Administrative Excl. Other377369294
Research and Development11911782
Other Operating Expense6457228
Operating Income2233-73
Interest Expense151517
Unusual Expense
———
Non-Operating Income (Expense)-52-24
Net Income Before Taxes1417-63
Income Taxes81036
Consolidated Net Income57-100
Net Income From Continuing Operations57-100
Net Income57-100
EPS (Recurring)0.120.16-2.15
EPS (Basic, Before Extraordinaries)0.120.16-2.15
EPS (Diluted)0.120.16-2.15
EBITDA11812329
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio186.08161.75—
Price To Sales Ratio1.221.60—
Gross Margin79.3279.4875.75
Operating Margin2.994.55-10.41
Net Margin0.680.96-14.27
Shares Outstanding404546
Market Capitalization8931,165—
Operating Lease Expense
———
Insider Trading Volume
$23.50$21.62$19.74$17.87$15.99● Close Price0.00K156.69K313.38K470.06K626.75KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
RIKER LAURENSenior Vice President, FinanceJun 11 '26Sale23.506,115143,70362,284Jun 12 12:00 AM
WILLIAMS KRISTENChief Administrative OfficerJun 04 '26Sale22.2710,259228,468167,062Jun 05 12:00 AM
Cross ShawnChief Financial OfficerApr 23 '26Option Exercise16.4525,882425,758150,000Apr 24 12:00 AM
Cross ShawnChief Financial OfficerApr 23 '26Sale25.1612,941325,596105,341Apr 24 12:00 AM
Cross ShawnChief Financial OfficerApr 22 '26Option Exercise16.453,00049,350162,941Apr 22 12:00 AM
Cross ShawnChief Financial OfficerApr 22 '26Sale25.011,50037,515105,341Apr 22 12:00 AM
Cross ShawnChief Financial OfficerApr 21 '26Option Exercise16.455,69093,600164,441Apr 22 12:00 AM
Cross ShawnChief Financial OfficerApr 20 '26Option Exercise16.4515,428253,790167,286Apr 22 12:00 AM
Cross ShawnChief Financial OfficerApr 20 '26Sale25.147,714193,930105,341Apr 22 12:00 AM
SLONIN JONATHANChief Medical OfficerMar 17 '26Sale22.823,26174,416223,640Mar 19 12:00 AM
Froimson MarkDirectorMar 17 '26Sale21.8150010,90520,136Mar 19 12:00 AM
WILLIAMS KRISTENChief Administrative OfficerFeb 02 '26Sale20.5313,137269,703131,303Feb 03 12:00 AM
RIKER LAURENSenior Vice President, FinanceFeb 02 '26Sale20.814,00083,24052,313Feb 03 12:00 AM
RIKER LAURENSenior Vice President, FinanceJan 05 '26Sale24.241,41634,32459,064Jan 06 12:00 AM
Cross ShawnChief Financial OfficerDec 10 '25Option Exercise16.4518,208299,522175,000Dec 11 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR